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Background: Historically, periodontal regeneration has focused predominantly on bone substitutes
and/or barrier membrane application to provide for defect fill and/or selected cell repopulation of the le-
sion. More recently, a number of technologies have evolved that can be viewed as emerging therapeutic
approaches for periodontal regeneration, and these technologies were considered in the review paper and
by the consensus group. The goal of this consensus report on emerging regenerative approaches for peri-
odontal hard and soft tissue reconstruction was to develop a consensus document based on the accom-
panying review paper and on additional materials submitted before and at the consensus group session.
Methods: The review paper was sent to all the consensus group participants in advance of the consen-
sus conference. In addition and also before the conference, individual consensus group members submit-
ted additional material for consideration by the group. At the conference, each consensus group
participant introduced themselves and provided disclosure of any potential conflicts of interest. The re-
view paper was briefly presented by two of the authors and discussed by the consensus group. A discus-
sion of each of the following topics then occurred based on the content of the review: a general summary
of the topic, implications for patient-reported outcomes, and suggested research priorities for the future.
As each topic was discussed based on the review article, supplemental information was then added that
the consensus group agreed on. Last, an updated reference list was created.
Results: The application of protein and peptide therapy, cell-based therapy, genetic therapy, application of
scaffolds, bone anabolics, and lasers were found to be emerging technologies for periodontal regeneration. Other
approaches included the following: 1) therapies directed at the resolution of inflammation; 2) therapies that took
into account the influence of the microbiome; 3) therapies involving the local regulation of phosphate and py-
rophosphate metabolism; and 4) approaches directed at harnessing current therapies used for other purposes.
The results indicate that, with most emerging technologies, the specific mechanisms of action are not well un-
derstood nor are the specific target cells identified. Patient-related outcomes were typically not addressed in the
literature. Numerous recommendations can bemade for future research priorities for both basic science and clin-
ical application of emerging therapies. The need to emphasize the importance of regeneration of a functional
periodontal organ system was noted. The predictability and efficacy of outcomes, as well as safety concerns
and the cost-to-benefit ratio were also identified as key factors for emerging technologies.
Conclusions: A number of technologies appear viable as emerging regenerative approaches for periodontal
hard and soft tissue regeneration and are expanding the potential of reconstructing the entire periodontal organ
system. The cost-to-benefit ratio and safety issues are important considerations for any new emerging therapies.
Clinical Recommendation: At this time, there is insufficient evidence on emerging periodontal regenerative
technologies to warrant definitive clinical recommendations. J Periodontol 2015;86(Suppl.):S153-S156.
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M
embers of the Emerging Regenerative Ap-
proaches for Periodontal Reconstruction con-
sensus group met and began with individual
introductions and provision of appropriate disclo-
sures. The authors of the written review provided
a summary of the construction and contents of
the review paper.1 Each member of this consensus
group provided comments on the review.
As an overview, one of the issues arising was the
question of defining what constitutes an emerging
technology. The group considered two broad categories:
1) products and components of products approved
by the US Food and Drug Administration (FDA) and 2)
non-approved therapeutic modalities. For example,
components of FDA-approved products are being
examined for periodontal regeneration and thus were
considered an emerging therapeutic approach. In ad-
dition, currently available therapeutics that have limited
data supporting their use in periodontal regeneration
were also considered an emerging technology.
We discussed the contents of the review paper
and made suggestions for additions. The consensus
group agreed with the contents of the review paper
and the scope of products and technologies that were
covered in the paper with the additions and com-
ments noted below.
Most of the emerging approaches discussed in the
review paper were focused on the concepts of tissue
engineering2 and also included other approaches.
The topics discussed included the following: 1)
protein and peptide therapy;3-8 2) cell-based ther-
apy;9 3) genetic therapy; 4) scaffolds;10 5) bone
anabolics; and 6) lasers. FDA-approved products
evaluated included the following: 1) enamel matrix
derivative; 2) recombinant human platelet-derived
growth factor; and 3) anorganic bone matrix. Non-
approved therapeutic modalities included the fol-
lowing: 1) recombinant human fibroblast growth
factor-2; 2) recombinant human growth differentia-
tion factor-5; 3) bone morphogenetic proteins (BMP-
2, BMP-7, BMP-6, andBMP-12); 4)parathyroidhormone/
teriparatide; 5) brain-derived neurotrophic factor; and
6) sclerostin antibodies.11 Cell-based therapies
included the following: 1) mesenchymal stem cells;
2) bone marrow stromal cells; 3) periodontal liga-
ment cells; 4) embryonic stem cells; and 5) induced
pluripotent stem cells. Gene therapies included viral
and non-viral vectors. Scaffolds are also promising
for delivery of growth factors and gene therapy and
may be composed of either natural or synthetic
polymeric materials.12,13 Finally, various types of
lasers were discussed.
In addition to the approaches highlighted in the
review, the consensus group recognized that many
of the therapeutics in current use are based on
fundamental knowledge and understanding of the
development of the periodontium.14-16 Furthermore,
the host inflammatory response should also be con-
sidered, as well as such interactions between the host
genome, epigenetics, and the microbiome.17-20 Areas
of future interestmight include inflammatory regulators
such as resolvins21 and interleukin-17 antibodies, as
well as phosphate/pyrophosphate local regulation.22
IMPLICATIONS OF REVIEW TO PATIENT-
RELATED CLINICAL OUTCOMES
The review did not identify any reports addressing
patient-reported outcomes. However, the review did
reveal clinical parameter-based outcomes of several
individualized approaches over various time periods,
with the longest follow-up being 3 years in one report
of 83 patients.23 Although there are multiple papers
focused on various emerging technologies, there are
no studies that allow for direct comparison of clinical
outcomes.
When dealing with emerging technologies, there
can be both positive and negative issues of clinician
adoption and patient acceptance of treatment.
Barriers to adopting this technology include lim-
ited evidence supporting efficacy and indications for
use. With emerging technologies, safety issues in-
clude unknown long-term effects along with known
risk for rare but serious side effects, such as sarcoma.
This is, in part, attributable to evaluation of such
emerging technologies in populations defined by
selected inclusion/exclusion criteria, further limiting
outcome assessments.
With any emerging technology, the cost-to-benefit
ratio for clinicians and patients must be determined.
For the clinician, peer and market pressures, surgical
time, technical complexity, healing times, pre-
dictability, liability, and cost must be considered.
For patients, experience of pain and morbidity,
adverse events, both short and long term, cost, time,
material (ethical and religious concerns), esthetic per-
ceptions, and satisfaction with treatment outcomes
should be considered.
RESEARCH PRIORITIES FOR THE FUTURE
With all emerging therapies, the prevalence, pre-
dictability, and efficacy of outcomes and safety
should be well defined. Future research should
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promote the goal of emerging technologies to re-
generate the periodontium as a functional organ
system. The review made a number of recommen-
dations, and the consensus group highlighted that
future studies should do the following: 1) develop
a non-invasive assessment of clinical periodontal
regeneration; 2) evaluate the efficacy and safety of
combining emerging and/or current therapies; 3)
validate existing and/or emerging therapies being
used ‘‘off label’’; 4) explore therapies developed for
other purposes for their application to periodontal
regeneration; 5) define the individual’s genetic and
epigenetic profile so that it can be used to personalize
the choice of therapy; 6) assess the effect of in-
dividual disease pathogenesis, etiology, and healing
potential on therapeutic treatment selection; 7) op-
timize the understanding of risk factors to aid in the
selection of appropriate therapy and the achievement
of enhanced outcomes to restore the structure and
function of the periodontium; 8) define molecular and
cellular mechanisms of the emerging therapy using
in vitro and in vivo models; 9) identify developmental
pathways of the periodontium for potential applica-
tion in regenerative therapy; 10) focus on developing
minimally invasive technologies to minimize pain
and morbidity without compromising outcomes; 11)
define what constitutes clinical success; and 12)
characterize the effect of the selected therapy on the
patient’s quality of life.
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setts), Nobel Biocare (Zürich, Switzerland), Institute
Straumann (Basel, Switzerland), Osteohealth (Shirley,
New York), Organogenesis (Canton, Massachusetts),
and Cytograft Tissue Engineering (Novato, California)
as well as advisor fees from Imaging Sciences Interna-
tional (Hatfield, Pennsylvania). Dr. Murakami has re-
ceived research funding and consulting fees from
Kaken Pharmaceutical (Tokyo, Japan). Dr. Rios has
received research funding from Osteology Foundation,
has served as a consultant for Geitslich Pharma (Wol-
husen, Switzerland) and Organogenesis, and his re-
search has been supported by the National Institutes
of Health/National Institute of Dental and Craniofacial
Research (1K23DE019872, R21DE023845-01A1, and
R56DE022787-01A1). Drs. Lin and Mandelaris report
no conflicts of interest related to this consensus report.
The 2014 Regeneration Workshop was hosted by the
American Academy of Periodontology (AAP) and sup-
ported in part by the AAP Foundation, Geistlich Pharma
North America, Colgate-Palmolive, and the Osteology
Foundation.
REFERENCES
1. Lin Z, Rios HF, Cochran DL. Emerging regenerative
approaches for periodontal reconstruction: A system-
atic review from the AAP regeneration workshop.
J Periodontol 2015;86(Suppl.):S134-S152.
2. Somerman M. Growth factors and periodontal engi-
neering: Where next? J Dent Res 2011;90:7-8.
3. AminHD,Olsen I,KnowlesJ,DardM,DonosN.A tyrosine-
rich amelogenin peptide promotes neovasculogenesis
in vitro and ex vivo. Acta Biomater 2014;10:1930-1939.
4. AminHD,Olsen I, Knowles JC,DonosN.Differential effect
of amelogenin peptides on osteogenic differentiation
in vitro: Identification of possible new drugs for bone repair
and regeneration. Tissue Eng Part A 2012;18:1193-1202.
5. Foster BL, Nagatomo KJ, Nociti FH Jr., et al. Central
role of pyrophosphate in acellular cementum forma-
tion. PLoS One 2012;7:e38393.
6. Iizuka S, Kudo Y, Yoshida M, et al. Ameloblastin
regulates osteogenic differentiation by inhibiting Src
kinase via cross talk between integrin beta1 and CD63.
Mol Cell Biol 2011;31:783-792.
7. Kakegawa A, Oida S, Gomi K, et al. Cytodifferentiation
activity of synthetic human enamel sheath protein
peptides. J Periodontal Res 2010;45:643-649.
8. Kanazashi M, Gomi K, Nagano T, Tanabe T, Arai T,
Fukae M. The 17-kDa sheath protein in enamel pro-
teins induces cementum regeneration in experimental
cavities created in a buccal dehiscence model of dogs.
J Periodontal Res 2006;41:193-199.
9. Arany PR, Cho A, Hunt TD, et al. Photoactivation of
endogenous latent transforming growth factor-beta1
directs dental stem cell differentiation for regeneration.
Sci Transl Med 2014;6:238ra69.
10. Costa PF, Vaquette C, Zhang Q, Reis RL, Ivanovski S,
Hutmacher DW. Advanced tissue engineering scaffold
design for regeneration of the complex hierarchical peri-
odontal structure. J Clin Periodontol 2014;41:283-294.
11. Das S, Sakthiswary R. Bone metabolism and histomor-
phometric changes in murine models treated with
sclerostin antibody: A systematic review. Curr Drug
Targets 2013;14:1667-1674.
12. Oortgiesen DA, Walboomers XF, Bronckers AL, Meijer
GJ, Jansen JA. Periodontal regeneration using an
injectable bone cement combined with BMP-2 or
FGF-2. J Tissue Eng Regen Med 2014;8:202-209.
13. Yamano S, Haku K, Yamanaka T, et al. The effect of
a bioactive collagenmembrane releasing PDGForGDF-5
on bone regeneration. Biomaterials 2014;35:2446-2453.
14. Cortellini P, Pini-Prato G, Nieri M, Tonetti MS. Minimally
invasive surgical technique and enamel matrix de-
rivative in intrabony defects: 2. Factors associated with
J Periodontol • February 2015 (Suppl.) Cochran, Cobb, Bashutski, et al.
S155
healing outcomes. Int J Periodontics Restorative Dent
2009;29:257-265.
15. Fukae M, Kanazashi M, Nagano T, Tanabe T, Oida S,
Gomi K. Porcine sheath proteins show periodontal liga-
ment regeneration activity. Eur J Oral Sci 2006;114
(Suppl. 1):212-218; discussion 254-256, 381-382.
16. Warotayanont R, Frenkel B, Snead ML, Zhou Y.
Leucine-rich amelogenin peptide induces osteogenesis
by activation of the Wnt pathway. Biochem Biophys
Res Commun 2009;387:558-563.
17. Hajishengallis G. Aging and its impact on innate
immunity and inflammation: Implications for peri-
odontitis. J Oral Biosci 2014;56:30-37.
18. Hajishengallis G, Sahingur SE. Novel inflammatory
pathways in periodontitis. Adv Dent Res 2014;26:
23-29.
19. Maekawa T, Abe T, Hajishengallis E, et al. Genetic and
intervention studies implicating complement C3 as
a major target for the treatment of periodontitis. J
Immunol 2014;192:6020-6027.
20. Moutsopoulos NM, Konkel J, Sarmadi M, et al. De-
fective neutrophil recruitment in leukocyte adhesion
deficiency type I disease causes local IL-17-driven
inflammatory bone loss. Sci Transl Med 2014;6:
229ra40.
21. Mustafa M, Zarrough A, Bolstad AI, et al. Resolvin D1
protects periodontal ligament. Am J Physiol Cell
Physiol 2013;305:C673-C679.
22. Rodrigues TL, Nagatomo KJ, Foster BL, Nociti FH,
Somerman MJ. Modulation of phosphate/pyrophosphate
metabolism to regenerate the periodontium: A novel
in vivo approach. J Periodontol 2011;82:1757-1766.
23. Nevins M, Kao RT, McGuire MK, et al. Platelet-derived
growth factor promotes periodontal regeneration in
localized osseous defects: 36-month extension results
from a randomized, controlled, double-masked clinical
trial. J Periodontol 2013;84:456-464.
Correspondence: Dr. David L. Cochran, Department of
Periodontics, University of Texas Health Science Center
at San Antonio Dental School, 7703 Floyd Curl Dr.,
San Antonio, TX 78240. Fax: 210/567-3393; e-mail:
cochran@uthscsa.edu.
Submitted June 24, 2014; accepted for publication August
19, 2014.
Emerging Regenerative Approaches for Periodontal Reconstruction Volume 86 • Number 2 (Suppl.)
S156
